These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20920698)

  • 1. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients.
    Kawamura Y; Arase Y; Ikeda K; Hirakawa M; Hosaka T; Kobayashi M; Saitoh S; Yatsuji H; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Kumada H
    Am J Med; 2010 Oct; 123(10):951-956.e1. PubMed ID: 20920698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis.
    Kawamura Y; Ikeda K; Arase Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1739-46. PubMed ID: 18713301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma.
    Chiba T; Matsuzaki Y; Abei M; Shoda J; Tanaka N; Osuga T; Aikawa T
    Am J Gastroenterol; 1996 Jun; 91(6):1195-203. PubMed ID: 8651170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.
    Makiyama A; Itoh Y; Kasahara A; Imai Y; Kawata S; Yoshioka K; Tsubouchi H; Kiyosawa K; Kakumu S; Okita K; Hayashi N; Okanoue T
    Cancer; 2004 Oct; 101(7):1616-22. PubMed ID: 15378504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
    Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
    Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses.
    Wang CS; Yao WJ; Chang TT; Wang ST; Chou P
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2054-60. PubMed ID: 19549812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.
    Ikeda K; Saitoh S; Koida I; Arase Y; Tsubota A; Chayama K; Kumada H; Kawanishi M
    Hepatology; 1993 Jul; 18(1):47-53. PubMed ID: 7686879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center.
    Ikeda K; Arase Y; Saitoh S; Kobayashi M; Someya T; Hosaka T; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Kumada H
    Intervirology; 2006; 49(1-2):82-90. PubMed ID: 16166794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients.
    Fattovich G; Pantalena M; Zagni I; Realdi G; Schalm SW; Christensen E;
    Am J Gastroenterol; 2002 Nov; 97(11):2886-95. PubMed ID: 12425564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
    Arase Y; Kobayashi M; Suzuki F; Suzuki Y; Kawamura Y; Akuta N; Kobayashi M; Sezaki H; Saito S; Hosaka T; Ikeda K; Kumada H; Kobayashi T
    Hepatology; 2013 Mar; 57(3):964-73. PubMed ID: 22991257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necessities of interferon therapy in elderly patients with chronic hepatitis C.
    Ikeda K; Arase Y; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
    Am J Med; 2009 May; 122(5):479-86. PubMed ID: 19375558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients.
    Ohki T; Tateishi R; Sato T; Masuzaki R; Imamura J; Goto T; Yamashiki N; Yoshida H; Kanai F; Kato N; Shiina S; Yoshida H; Kawabe T; Omata M
    Clin Gastroenterol Hepatol; 2008 Apr; 6(4):459-64. PubMed ID: 18387499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of alcohol, cigarette smoking, and diabetes on occurrence of hepatocellular carcinoma in patients with transfusion-acquired hepatitis C virus infection who develop cirrhosis.
    Di Costanzo GG; De Luca M; Tritto G; Lampasi F; Addario L; Lanza AG; Tartaglione MT; Picciotto FP; Ascione A
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):674-9. PubMed ID: 18679071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.
    N'Kontchou G; Paries J; Htar MT; Ganne-Carrie N; Costentin L; Grando-Lemaire V; Trinchet JC; Beaugrand M
    Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1062-8. PubMed ID: 16844421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.
    Uenishi T; Nishiguchi S; Tanaka S; Yamamoto T; Takemura S; Kubo S
    J Surg Oncol; 2008 Oct; 98(5):358-62. PubMed ID: 18646001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.
    Imazeki F; Yokosuka O; Fukai K; Saisho H
    Hepatology; 2003 Aug; 38(2):493-502. PubMed ID: 12883494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection.
    Simó R; Lecube A; Genescà J; Esteban JI; Hernández C
    Diabetes Care; 2006 Nov; 29(11):2462-6. PubMed ID: 17065685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.